Prescient Therapeutics Ltd has released a press release.
Voluntary Suspension
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
In the deck
Earlier from Prescient Therapeutics
- Pause in Trading
- PTX-100 progresses to new dose, adds new site
- March 2020 Quarterly Update and Appendix 4C
- December 2019 Appendix 4C - Quarterly
- PTX-200 High Overall Response in Ph2a Breast Cancer trial
Later from Prescient Therapeutics
- PTX signs next-gen anti-cancer platform from Penn & Oxford
- Reinstatement to Official Quotation
- Trading Pause
- 2 PTX Assets Chosen in Doherty Institute COVID-19 Program
- June 2020 Quarterly Update and Appendix 4C
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics